Related Experiment Video

Updated: May 27, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Targeting the extracellular signal-regulated kinase pathway in cancer therapy

Michiaki Kohno1, Susumu Tanimura, Kei-ichi Ozaki

  • 1Laboratory of Cell Regulation, Department of Pharmaceutical Sciences, Graduate School of Biomedical Sciences, Nagasaki University, Japan. kohnom@nagasaki-u.ac.jp

Biological & Pharmaceutical Bulletin
|December 2, 2011
PubMed

Insights

Combining MEK inhibitors with conventional anticancer drugs enhances tumor cell death. This approach offers a promising strategy for developing safer and more effective cancer chemotherapies by reducing drug dosages.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling Pathways

Background:

  • The extracellular signal-regulated kinase (ERK) pathway regulates critical cellular functions like proliferation and survival.
  • This pathway is frequently overactive in human cancers, making it a key therapeutic target.
  • Solely blocking the ERK pathway yields limited efficacy, primarily cytostatic effects rather than tumor cell death.

Purpose of the Study:

  • To investigate the efficacy of combining MEK inhibitors with conventional anticancer agents.
  • To determine if MEK inhibition sensitizes cancer cells to apoptosis.
  • To explore a novel strategy for enhancing cancer treatment outcomes.

Main Methods:

  • Utilized MEK inhibitors to block the constitutively activated ERK pathway in cancer cells.
  • Co-administered MEK inhibitors with microtubule-destabilizing agents and histone deacetylase inhibitors.
  • Evaluated cellular responses, including apoptotic cell death, in vitro and in vivo using tumor xenografts.

Main Results:

  • MEK inhibition sensitized tumor cells to apoptosis induced by cytotoxic anticancer agents.
  • Low doses of conventional anticancer drugs, when combined with MEK inhibitors, effectively killed tumor cells.
  • Demonstrated enhanced efficacy in both in vitro and in vivo (tumor xenografts) models.

Conclusions:

  • Combining cytostatic MEK inhibitors with conventional anticancer drugs (microtubule-destabilizing or histone deacetylase inhibitors) represents a viable strategy.
  • This combination therapy can lead to enhanced anticancer efficacy and potentially safer treatments.
  • Lowering the required doses of cytotoxic drugs through combination therapy improves the therapeutic index.

More Related Videos

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells09:20

Reliably Engineering and Controlling Stable Optogenetic Gene Circuits in Mammalian Cells

Published on: July 6, 2021

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...